| Literature DB >> 31069787 |
A R Young1, J Narbutt2, G I Harrison1, K P Lawrence1, M Bell3, C O'Connor3, P Olsen4, K Grys1, K A Baczynska5, M Rogowski-Tylman6, H C Wulf4, A Lesiak2, P A Philipsen4.
Abstract
BACKGROUND: Sunlight contains ultraviolet (UV)A and UVB radiation. UVB is essential for vitamin D synthesis but is the main cause of sunburn and skin cancer. Sunscreen use is advocated to reduce the sun's adverse effects but may compromise vitamin D status.Entities:
Year: 2019 PMID: 31069787 PMCID: PMC6899952 DOI: 10.1111/bjd.17888
Source DB: PubMed Journal: Br J Dermatol ISSN: 0007-0963 Impact factor: 9.302
Summary of study locations, sunscreen use, age and body surface area
| Group | A | B | C | D | All | Main conclusions from between‐group comparisons |
|---|---|---|---|---|---|---|
| Location | Tenerife | Tenerife | Tenerife | Łódź | NA | |
| Sunscreen use | High UVA‐PF (label SPF 15) | Low UVA‐PF (label SPF 15) | Discretionary | None | NA | |
| No. participants | 20 | 20 | 22 | 17 | 79 | |
| Age (years), mean ± SD | 33 ± 7 | 38 ± 7 | 33 ± 8 | 34 ± 9 | 34 ± 8 | No age differences ( |
| BSA (m2), mean ± SD | 1·81 ± 0·23 | 1·90 ± 0·25 | 1.81 ± 0.16 | 1.74 ± 0.12 | 1·82 ± 0·20 | No BSA differences for M, F and M + F ( |
Fuller details of all aspects apart from vitamin D status are described in Narbutt et al.31 As previously reported,31 all nonvitamin D parameters were normally distributed. Values are mean ± SD. BSA, body surface area; F, female; M, male; NA, not applicable; PF, protection factor; SPF, sun protection factor.
Summary of skin type and sex of participants
| Group | A | B | C | D | All | Main conclusions from between‐group comparisons |
|---|---|---|---|---|---|---|
| II | 13 | 12 | 15 | 7 | 47 | Significant skin type difference in all groups ( |
| III | 7 | 8 | 5 | 10 | 30 | |
| IV | 0 | 0 | 2 | 0 | 2 | |
| Male | 8 | 11 | 8 | 2 | 29 | No sex difference in all groups ( |
| Female | 12 | 9 | 14 | 15 | 50 |
Summary of actual sun protection factor (SPF), sunscreen application, ultraviolet radiation (UVR) exposure, erythema and 25‐dihydroxyvitamin D3 [25(OH)D3] and study results
| Group | A | B | C | D | All | Main conclusions from between‐group comparisons |
|---|---|---|---|---|---|---|
| Actual SPF, mean ± SD | 18·9 ± 2·8 | 17·7 ± 2·7 | ND | NA | NA | No difference between SPF in A and B ( |
| Sunscreen application thickness (mg cm−2), mean ± SD | 2·43 ± 0·55 | 2·44 ± 0·48 | ND | NA | NA | No difference in sunscreen application thickness in groups A and B ( |
| UVR exposure (SED), mean ± SD | 41·0 ± 13·6 | 38·6 ± 15·4 | 49·4 ± 18·4 | 1·9 ± 3·4 | 43·2 ± 16·5 | No SED difference in A, B and C ( |
| Hours outside, mean ± SD | 39·5 ± 6·5 | 38·0 ± 6·4 | 46·7 ± 10·0 | 3·7 ± 3·9 | 41·6 ± 8·7 | No differences in A and B ( |
| Erythema (reflectance spectroscopy) | No | No | Yes | NA | NA | No differences in A and B on five exposed body sites ( |
|
Preholiday 25(OH)D3 (nmol L−1), mean ± SD | 67·0 ± 31·5 | 59·0 ± 24·5 | 59·9 ± 24·7 | 47·9 ± 23·8 | 58·9 ± 26·7 | No baseline 25(OH)D3 differences in A, B, C and D ( |
|
Postholiday 25(OH)D3 (nmol L−1), mean ± SD | 85·9 ± 25·3 | 72·0 ± 21·5 | 88·0 ± 20·4 | 45·4 ± 20·9 | NA | With baseline adjustment, A, B and C higher 25(OH)D3 than D ( |
| Δ25(OH)D3 (nmol L−1) | 19·0 ± 14·2 | 13·0 ± 11·4 | 28·0 ± 16·5 | –2·5 ± 5·6 | NA | With baseline adjustment, A, B and C higher 25(OH)D3 than D ( |
|
| < 0·001 | < 0·001 | < 0·001 | 0·087 | NA | NA |
| Preholiday % < 50 nmol L−1 25(OH)D3 | 30 | 35 | 32 | 71 | 41 | High % with < 50 nmol L−1 25(OH)D3, particularly in group D |
| Postholiday % < 50 nmol L−1 25(OH)D3 | 0 | 15 | 5 | 65 | NA | A reduction in % with < 50 nmol L−1 25(OH)D3 in holiday groups |
Fuller details of all aspects apart from vitamin D status are described in Narbutt et al.31 As previously reported,31 all nonvitamin D parameters were normally distributed, as are pre‐ and postholiday 25(OH)D3 and the differences between them. The addition of the 25(OH)D2 data (Fig. S1; see Supporting Information) increases the combined means from ~4 to 6 nmol L−1. Note that the data on sunscreen application thickness are based on the first application from each tube to 85% of body surface area and that the group D exposure data are based on 13 of 17 volunteers from whom there was a full 7‐day dataset. Values are mean ± SD. ND, no data; NA, not applicable; SED, standard erythema dose; SPF, sun protection factor. aExcludes group D.
Figure 1Solar ultraviolet radiation exposure during the 7‐day holiday in Tenerife. (a) Mean half‐hourly ambient and study group exposure [standard erythema doses (SEDs) per 0·5 h]. Groups A, B (sunscreen intervention) and C (discretionary sunscreen use) received 14% [95% confidence interval (CI) 11–17], 13% (95% CI 10–16) and 17% (95% CI 14–20) of ambient, respectively (based on area under the curve). (b) Erythemally effective energy (J) received at the skin surface. This is the product of SED (expressed as 100 J m−2) and body surface area (m2) exposed each 30 min in groups A, B and C. The individual data are shown in Figure S2 (see Supporting Information).
Figure 2Ultraviolet radiation (UVR) transmittance of the two intervention sunscreens. For full details of sunscreen properties, including UVR absorption properties (as monochromatic protection factors) see Narbutt et al.31 The inset shows the transmittance in the UVB region. Based on area under the curve, sunscreen A (with high UVA‐protection factor) transmits ~20% more UVB than sunscreen B (with low UVA‐protection factor).
Figure 3Linear relationship between 25(OH)D3 measurements from two independent laboratories. The linear regression (n = 149) equation is y = 1·01(± 0·03)x + 6·73(± 1·86) and the slope is highly significant (P < 0·001) with r 2 = 0·91. Errors are SE. The intercept is consistent with the Bland–Altman test (Fig. S3; see Supporting Information). Colour squares refer to study group and the shapes (Ο and Δ) refer to pre‐ and postholiday, respectively; dotted lines represent the 50 nmol L−1 boundary between vitamin D3 insufficiency and sufficiency. 25(OH)D3, 25‐hydroxyvitamin D3; BBH, Bispebjerg Hospital; BCH, Birmingham City Hospital.